Hormonal Contraceptives Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others), By Hormone (Combination Hormonal Contraceptives, Progestin Only), By Region and Competition, 2020-2030F
Market Overview
Global Hormonal Contraceptives Market was valued at USD 17.25 Billion in 2024 and is expected to reach USD 25.57 Billion by 2030 with a CAGR of 6.78% during the forecast period. The global market for Hormonal Contraceptives is experiencing significant growth, driven by the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, ahavetion of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen.
Key Market Drivers
Rising Government Initiatives to Promote Family Planning and Reproductive Health
One of the primary drivers of growth in the global hormonal contraceptives market is the significant investment by governments and international health organizations in reproductive health and family planning programs. Hormonal contraceptives—including oral pills, patches, injections, implants, and vaginal rings—form the cornerstone of modern contraception. Their widespread availability and integration into public health systems are largely supported by government policies that aim to reduce unintended pregnancies, maternal mortality, and child morbidity. The World Health Organization (WHO) states that around 257 million women globally who want to avoid pregnancy are not using safe or modern contraceptive methods. To address this unmet need, numerous governments have scaled up access to hormonal contraceptives through national programs. For instance, the U.S. federal Title X Family Planning Program supports clinics in offering affordable or free birth control to low-income individuals. According to the Office of Population Affairs (OPA), Title X clinics served 1.5 million individuals in 2022 alone, and over 99% of those clients received contraceptive services.
In developing countries, such as India, the Ministry of Health and Family Welfare operates the National Family Planning Program, which provides subsidized contraceptives through public health centers. As of 2023, the Indian government distributed over 20 million cycles of oral contraceptive pills under its Mission Parivar Vikas scheme. These expansive efforts ensure continuous market demand for hormonal contraceptives and stimulate innovation and supply chain efficiency. In effect, public health policies aimed at increasing contraceptive prevalence are driving hormonal contraceptive market growth across regions.
Key Market Challenges
Health Risks and Side Effects Associated with Hormonal Contraceptives
Despite their widespread use and effectiveness, hormonal contraceptives are associated with various health risks and side effects, which pose a significant challenge to market growth. Hormonal contraceptives function by altering a woman's hormone levels to prevent ovulation, and this hormonal interference can lead to adverse effects such as mood swings, weight gain, nausea, headaches, and menstrual irregularities. More serious risks include an increased likelihood of blood clots, cardiovascular complications, and, in rare cases, certain types of cancer. A study by the National Cancer Institute (NCI) reported a slight increase in the risk of breast and cervical cancer among long-term users of hormonal contraceptives, although they may reduce the risk of ovarian and endometrial cancers.
In 2019, the U.S. Food and Drug Administration (FDA) updated warnings on combined hormonal contraceptives (CHCs) about the risk of venous thromboembolism (VTE), especially for products containing drospirenone. Similarly, regulatory agencies in Europe, such as the European Medicines Agency (EMA), have recommended stronger warnings and educational efforts to ensure informed use. Concerns about side effects can lead to discontinuation or switching to non-hormonal methods, particularly in high-risk populations such as smokers over 35, obese individuals, and those with hypertension or a family history of thrombotic disorders. These health considerations reduce user confidence and affect market penetration, especially among new adopters. As awareness of potential adverse effects grows, particularly through social media and health advocacy platforms, it may hinder widespread adoption unless offset by education, personalized medical guidance, and the development of safer formulations.
Key Market Trends
Increasing Preference for Long-Acting Reversible Contraceptives (LARCs)
A prominent trend reshaping the hormonal contraceptives landscape is the growing preference for Long-Acting Reversible Contraceptives (LARCs) such as hormonal intrauterine devices (IUDs) and subdermal implants. These methods offer extended protection ranging from three to ten years, minimal maintenance, and high efficacy—qualities that are increasingly appealing to women globally, particularly those seeking convenience and long-term reproductive autonomy. According to the U.S. Centers for Disease Control and Prevention (CDC), LARCs have the lowest failure rates among contraceptive methods—less than 1%—compared to 7% for oral contraceptive pills. This reliability, combined with a low requirement for user adherence, has fueled rapid adoption, especially in developed countries with well-established healthcare systems.
Government programs are also promoting LARCs as part of comprehensive reproductive healthcare. For instance, the UK's National Health Service (NHS) includes hormonal IUDs in its publicly funded contraceptive offerings. In the U.S., state-level Medicaid expansion has been linked to increased access and uptake of LARCs, particularly in underserved populations. A report from the Kaiser Family Foundation found that the use of LARCs among U.S. women aged 15–44 increased from 8.5% in 2009 to 14% in 2020. In low- and middle-income countries, international bodies like UNFPA and USAID have rolled out LARC-focused initiatives to reduce unmet contraceptive needs. These global efforts, combined with innovations in hormonal implant technologies, are likely to sustain the rising demand for LARCs over the coming decade.
Key Market Players
In this report, the Global Hormonal Contraceptives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Hormonal Contraceptives Market.
Available Customizations:
Global Hormonal Contraceptives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Global Hormonal Contraceptives Market was valued at USD 17.25 Billion in 2024 and is expected to reach USD 25.57 Billion by 2030 with a CAGR of 6.78% during the forecast period. The global market for Hormonal Contraceptives is experiencing significant growth, driven by the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, ahavetion of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen.
Key Market Drivers
Rising Government Initiatives to Promote Family Planning and Reproductive Health
One of the primary drivers of growth in the global hormonal contraceptives market is the significant investment by governments and international health organizations in reproductive health and family planning programs. Hormonal contraceptives—including oral pills, patches, injections, implants, and vaginal rings—form the cornerstone of modern contraception. Their widespread availability and integration into public health systems are largely supported by government policies that aim to reduce unintended pregnancies, maternal mortality, and child morbidity. The World Health Organization (WHO) states that around 257 million women globally who want to avoid pregnancy are not using safe or modern contraceptive methods. To address this unmet need, numerous governments have scaled up access to hormonal contraceptives through national programs. For instance, the U.S. federal Title X Family Planning Program supports clinics in offering affordable or free birth control to low-income individuals. According to the Office of Population Affairs (OPA), Title X clinics served 1.5 million individuals in 2022 alone, and over 99% of those clients received contraceptive services.
In developing countries, such as India, the Ministry of Health and Family Welfare operates the National Family Planning Program, which provides subsidized contraceptives through public health centers. As of 2023, the Indian government distributed over 20 million cycles of oral contraceptive pills under its Mission Parivar Vikas scheme. These expansive efforts ensure continuous market demand for hormonal contraceptives and stimulate innovation and supply chain efficiency. In effect, public health policies aimed at increasing contraceptive prevalence are driving hormonal contraceptive market growth across regions.
Key Market Challenges
Health Risks and Side Effects Associated with Hormonal Contraceptives
Despite their widespread use and effectiveness, hormonal contraceptives are associated with various health risks and side effects, which pose a significant challenge to market growth. Hormonal contraceptives function by altering a woman's hormone levels to prevent ovulation, and this hormonal interference can lead to adverse effects such as mood swings, weight gain, nausea, headaches, and menstrual irregularities. More serious risks include an increased likelihood of blood clots, cardiovascular complications, and, in rare cases, certain types of cancer. A study by the National Cancer Institute (NCI) reported a slight increase in the risk of breast and cervical cancer among long-term users of hormonal contraceptives, although they may reduce the risk of ovarian and endometrial cancers.
In 2019, the U.S. Food and Drug Administration (FDA) updated warnings on combined hormonal contraceptives (CHCs) about the risk of venous thromboembolism (VTE), especially for products containing drospirenone. Similarly, regulatory agencies in Europe, such as the European Medicines Agency (EMA), have recommended stronger warnings and educational efforts to ensure informed use. Concerns about side effects can lead to discontinuation or switching to non-hormonal methods, particularly in high-risk populations such as smokers over 35, obese individuals, and those with hypertension or a family history of thrombotic disorders. These health considerations reduce user confidence and affect market penetration, especially among new adopters. As awareness of potential adverse effects grows, particularly through social media and health advocacy platforms, it may hinder widespread adoption unless offset by education, personalized medical guidance, and the development of safer formulations.
Key Market Trends
Increasing Preference for Long-Acting Reversible Contraceptives (LARCs)
A prominent trend reshaping the hormonal contraceptives landscape is the growing preference for Long-Acting Reversible Contraceptives (LARCs) such as hormonal intrauterine devices (IUDs) and subdermal implants. These methods offer extended protection ranging from three to ten years, minimal maintenance, and high efficacy—qualities that are increasingly appealing to women globally, particularly those seeking convenience and long-term reproductive autonomy. According to the U.S. Centers for Disease Control and Prevention (CDC), LARCs have the lowest failure rates among contraceptive methods—less than 1%—compared to 7% for oral contraceptive pills. This reliability, combined with a low requirement for user adherence, has fueled rapid adoption, especially in developed countries with well-established healthcare systems.
Government programs are also promoting LARCs as part of comprehensive reproductive healthcare. For instance, the UK's National Health Service (NHS) includes hormonal IUDs in its publicly funded contraceptive offerings. In the U.S., state-level Medicaid expansion has been linked to increased access and uptake of LARCs, particularly in underserved populations. A report from the Kaiser Family Foundation found that the use of LARCs among U.S. women aged 15–44 increased from 8.5% in 2009 to 14% in 2020. In low- and middle-income countries, international bodies like UNFPA and USAID have rolled out LARC-focused initiatives to reduce unmet contraceptive needs. These global efforts, combined with innovations in hormonal implant technologies, are likely to sustain the rising demand for LARCs over the coming decade.
Key Market Players
- Abbvie, Inc.
- Afaxys, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Merck KGaA
- Organon Group of Companies
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Lupin Pharmaceuticals, Inc.
- Pregna International Ltd.
In this report, the Global Hormonal Contraceptives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Hormonal Contraceptives Market, By Method:
- Pill
- Intrauterine Device
- Injectable
- Vaginal Ring
- Implant
- Others
- Hormonal Contraceptives Market, By Hormone:
- Combination Hormonal Contraceptives
- Progestin Only
- Hormonal Contraceptives Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Hormonal Contraceptives Market.
Available Customizations:
Global Hormonal Contraceptives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL HORMONAL CONTRACEPTIVES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
6.2.3. By Region
6.2.4. By Company (2024)
6.3. Market Map
6.3.1. By Method
6.3.2. By Hormone
6.3.3. By Region
7. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Method
7.2.2. By Hormone
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States Hormonal Contraceptives Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Method
7.3.1.2.2. By Hormone
7.3.2. Canada Hormonal Contraceptives Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Method
7.3.2.2.2. By Hormone
7.3.3. Mexico Hormonal Contraceptives Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Method
7.3.3.2.2. By Hormone
8. EUROPE HORMONAL CONTRACEPTIVES MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Method
8.2.2. By Hormone
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Hormonal Contraceptives Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Method
8.3.1.2.2. By Hormone
8.3.2. Germany Hormonal Contraceptives Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Method
8.3.2.2.2. By Hormone
8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Method
8.3.3.2.2. By Hormone
8.3.4. Italy Hormonal Contraceptives Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Method
8.3.4.2.2. By Hormone
8.3.5. Spain Hormonal Contraceptives Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Method
8.3.5.2.2. By Hormone
9. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Method
9.2.2. By Hormone
9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Hormonal Contraceptives Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Method
9.3.1.2.2. By Hormone
9.3.2. India Hormonal Contraceptives Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Method
9.3.2.2.2. By Hormone
9.3.3. Japan Hormonal Contraceptives Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Method
9.3.3.2.2. By Hormone
9.3.4. South Korea Hormonal Contraceptives Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Method
9.3.4.2.2. By Hormone
9.3.5. Australia Hormonal Contraceptives Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Method
9.3.5.2.2. By Hormone
10. SOUTH AMERICA HORMONAL CONTRACEPTIVES MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Method
10.2.2. By Hormone
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Hormonal Contraceptives Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Method
10.3.1.2.2. By Hormone
10.3.2. Argentina Hormonal Contraceptives Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Method
10.3.2.2.2. By Hormone
10.3.3. Colombia Hormonal Contraceptives Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Method
10.3.3.2.2. By Hormone
11. MIDDLE EAST AND AFRICA HORMONAL CONTRACEPTIVES MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Method
11.2.2. By Hormone
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Hormonal Contraceptives Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Method
11.3.1.2.2. By Hormone
11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Method
11.3.2.2.2. By Hormone
11.3.3. UAE Hormonal Contraceptives Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Method
11.3.3.2.2. By Hormone
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. SWOT ANALYSIS: GLOBAL HORMONAL CONTRACEPTIVES MARKET
16. COMPETITIVE LANDSCAPE
16.1. Abbvie, Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (As Reported)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.7. SWOT Analysis
16.2. Afaxys, Inc.
16.3. Teva Pharmaceuticals Industries Ltd.
16.4. Bayer AG
16.5. Merck KGaA
16.6. Organon Group of Companies
16.7. Pfizer Inc.
16.8. Johnson & Johnson Services, Inc.
16.9. Lupin Pharmaceuticals, Inc.
16.10. Pregna International Ltd.
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL HORMONAL CONTRACEPTIVES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
6.2.3. By Region
6.2.4. By Company (2024)
6.3. Market Map
6.3.1. By Method
6.3.2. By Hormone
6.3.3. By Region
7. NORTH AMERICA HORMONAL CONTRACEPTIVES MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Method
7.2.2. By Hormone
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States Hormonal Contraceptives Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Method
7.3.1.2.2. By Hormone
7.3.2. Canada Hormonal Contraceptives Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Method
7.3.2.2.2. By Hormone
7.3.3. Mexico Hormonal Contraceptives Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Method
7.3.3.2.2. By Hormone
8. EUROPE HORMONAL CONTRACEPTIVES MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Method
8.2.2. By Hormone
8.2.3. By Country
8.3. Europe: Country Analysis
8.3.1. France Hormonal Contraceptives Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Method
8.3.1.2.2. By Hormone
8.3.2. Germany Hormonal Contraceptives Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Method
8.3.2.2.2. By Hormone
8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Method
8.3.3.2.2. By Hormone
8.3.4. Italy Hormonal Contraceptives Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Method
8.3.4.2.2. By Hormone
8.3.5. Spain Hormonal Contraceptives Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Method
8.3.5.2.2. By Hormone
9. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Method
9.2.2. By Hormone
9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Hormonal Contraceptives Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Method
9.3.1.2.2. By Hormone
9.3.2. India Hormonal Contraceptives Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Method
9.3.2.2.2. By Hormone
9.3.3. Japan Hormonal Contraceptives Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Method
9.3.3.2.2. By Hormone
9.3.4. South Korea Hormonal Contraceptives Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Method
9.3.4.2.2. By Hormone
9.3.5. Australia Hormonal Contraceptives Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Method
9.3.5.2.2. By Hormone
10. SOUTH AMERICA HORMONAL CONTRACEPTIVES MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Method
10.2.2. By Hormone
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Hormonal Contraceptives Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Method
10.3.1.2.2. By Hormone
10.3.2. Argentina Hormonal Contraceptives Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Method
10.3.2.2.2. By Hormone
10.3.3. Colombia Hormonal Contraceptives Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Method
10.3.3.2.2. By Hormone
11. MIDDLE EAST AND AFRICA HORMONAL CONTRACEPTIVES MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Method
11.2.2. By Hormone
11.2.3. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Hormonal Contraceptives Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Method
11.3.1.2.2. By Hormone
11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Method
11.3.2.2.2. By Hormone
11.3.3. UAE Hormonal Contraceptives Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Method
11.3.3.2.2. By Hormone
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Developments
13.2. Mergers & Acquisitions
13.3. Product Launches
14. PORTERS FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. SWOT ANALYSIS: GLOBAL HORMONAL CONTRACEPTIVES MARKET
16. COMPETITIVE LANDSCAPE
16.1. Abbvie, Inc.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (As Reported)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.7. SWOT Analysis
16.2. Afaxys, Inc.
16.3. Teva Pharmaceuticals Industries Ltd.
16.4. Bayer AG
16.5. Merck KGaA
16.6. Organon Group of Companies
16.7. Pfizer Inc.
16.8. Johnson & Johnson Services, Inc.
16.9. Lupin Pharmaceuticals, Inc.
16.10. Pregna International Ltd.
17. STRATEGIC RECOMMENDATIONS
18. ABOUT US & DISCLAIMER
